Hutchmed (China) Limited Appointment of Non--Executive Director (6322L)

TIDMHCM

RNS Number : 6322L

Hutchmed (China) Limited

16 May 2022

Appointment of Non-Executive Director

Hong Kong, Shanghai & Florham Park, NJ - Monday, May 16, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 and he will hold office until the next annual general meeting ("AGM") of HUTCHMED when he will stand for re-election.

The Board of HUTCHMED considers that the appointment of Mr Sun will provide significant benefits to HUTCHMED in view of his experience in capital markets, M&A and business strategy. Aged 42, Mr Sun has been the Managing Director and Head of China Healthcare for General Atlantic since 2018, in charge of private equity investment and portfolio management in the healthcare and life sciences sectors. General Atlantic owns approximately 3% of the ordinary shares of HUTCHMED, through its affiliate General Atlantic Singapore HCM Pte. Ltd.

Mr Simon To, Chairman of HUTCHMED, said, "On behalf of the Board, I would like to extend a warm welcome to Mr Sun. I believe his appointment will further strengthen our Board and we look forward to leveraging the wealth of experience that he brings to the table from his career in life sciences and healthcare investment."

Before joining General Atlantic, Mr Sun was the Founding Partner of Huatai Healthcare Investment Fund, successfully leading the investment in Mindray Medical, which is listed on Shenzhen Stock Exchange (SZSE:300760). Prior to that, Mr Sun held various investment roles at Credit Suisse and OrbiMed, and a strategy consultant role at McKinsey & Company, all in the healthcare sector. Mr Sun holds a Bachelor of Science degree in Mathematics and Physics from Tsinghua University. He also holds a Master of Arts degree in neuroscience from the Johns Hopkins University.

Mr Sun also has relevant Board experience with both publicly listed and private companies, having held the following directorships in the past five years:

 
Current Directorships:                    Previous Directorships in the last five years: 
  Adagene Inc. (Nasdaq:ADAG)                 Biotheus Inc. 
  Adagene (Hong Kong) Limited                CANbridge Pharmaceuticals Inc. (HKEX:1228) 
  Adagene (Suzhou) Ltd                       Huatai Healthcare Investment Fund 
  Genesis MedTech Group Inc.                 Ocumension Therapeutics Inc. (HKEX:1477) 
  Hong Kong Asia Medical Holding Limited 
 

Under the terms of the appointment of Mr Sun as a non-executive director of the Company until the next AGM, he has agreed that he will not receive any fee for his service and that his appointment will be renewed for successive 12-month periods, unless he is not re-elected at the next AGM or his appointment is otherwise terminated earlier by either party in writing.

Appointment Regulatory Disclosures

Save for the appointments listed above, Mr Sun has held no other directorships during the period of five years prior to his appointment as a director of HUTCHMED. Save for his role with General Atlantic, Mr Sun does not have any relationship with any Directors, senior management or substantial or controlling shareholders of HUTCHMED. Mr Sun does not have any interest in the ordinary shares of HUTCHMED within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong).

Save for the information disclosed above, there is no other information in relation to Mr Sun that is required to be disclosed pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies or Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there are no other matters concerning the appointment of Mr Sun that are required to be brought to the attention of the shareholders of HUTCHMED.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharma-ceutical company. It is committed to the discovery and global develop-ment and commercial-ization of targeted therapies and immuno-therapies for the treatment of cancer and immuno-logical diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,700 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President     [phone] 
  Annie Cheng, Vice President         [phone] 
 
Media Enquiries 
  Americas - Brad Miles,              [phone] (Mobile) 
   Solebury Trout                      [e-mail] 
  Europe - Ben Atwell / Alex Shaw,    [phone] / [phone] (Mobile) / [phone] (Mobile) 
   FTI Consulting                      [e-mail] 
  Asia - Zhou Yi,                     [phone] (Mobile) 
   Brunswick                           [e-mail] 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley, 
   Panmure Gordon (UK) Limited        [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBQLFFLELEBBF

(END) Dow Jones Newswires

May 16, 2022 07:00 ET (11:00 GMT)